Anti-osteoporosis

4',7-Isoflavandiol
Catalog No: CFN90723

4',7-Isoflavandiol, an estrogen metabolite, affects the ability of soy nuts to improve cardiovascular risk factors. 4',7-Isoflavandiol is a potential anticancer agent against HeLa, with possible mechanisms involved in ROS generation and mitochondrial membrane alteration; it may advance breast cancer potential via up-regulation of the eukaryotic initiation factor 4GI (eIF4GI).

Baohuoside VII
Catalog No: CFN90765

Baohuoside aglycone possesses cardioprotective effect in prevention of ischemia/ reperfusion injury and reduce the myocardial infraction, the mechnism is due to the reduction of the injury of free radicals. Baohuoside VII in vivo exhibits significant anti-osteoporosis activity.

Alliin
Catalog No: CFN93533

Alliin has antiglycating potential , it offers protection against glucose or methyglyoxal induced glycation of superoxide dismutase, hence is expected to have therapeutic potential in the prevention of glycation-mediated diabetic complications. Alliin has anti-inflammatory activity, it protects against Lipopolysaccharides (LPS)-induced acute lung injury (ALI) by activating PPARγ, which subsequently inhibits LPS-induced NF-κB activation and inflammatory response; alliin has an inhibitory effect in osteoclasteogenesis with a dose-dependent manner via blocking the c-Fos-NFATc1 signaling pathway, it could be a potential therapeutic agent in the treatment of osteoporosis. Alliin and sabinene have detectable levels of antimicrobial activity.

Veraguensin
Catalog No: CFN00451

Veraguensin shows activity against trypomastigote T. cruzi., it shows high antileishmanial activity. Veraguensin and galgravin can inhibit bone resorption and may offer novel compounds for the development of drugs to treat bone-destructive diseases such as osteoporosis.